In celebration of our 15 Year Anniversary, Academic Editor Ronald CW Ma highlights advancements published in PLOS Medicine in diabetes research and care, including improved precision medicine.
Happy 15th Birthday to PLOS Medicine! I still remember reading about the PLOS journals and the idea of making science accessible to all back when PLoS was first launched. It is amazing how far the Open Access movement has developed, how far that idea has advanced and how scientific publishing has been revolutionized. Congratulations PLOS Medicine on this important milestone!
Among the many articles that I have enjoyed reading in PLOS Medicine over the years, I would like to highlight two for sharing with other readers on this special occasion.
1) Event Rates, Hospital Utilization, and Costs Associated with Major Complications of Diabetes: A Multicountry Comparative Analysis
This paper by Philip Clarke and colleagues from the ADVANCE Collaborative Group, published back in 2010, highlighted the significant economic burden of diabetes and rates of hospitalization resulting from diabetes co-morbidities, using data from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study, a landmark multi-centre trial on the treatment of diabetes conducted in 20 countries. Within the ADVANCE trial settings, the study demonstrated important differences in the rates of hospitalization for different diabetes complications in different regions of the world (Asia, Eastern Europe, and established market economies such as Australia, New Zealand and Canada), mirroring epidemiological observations of comparative higher nephropathy rates, higher stroke risk, and lower risks of coronary artery disease among Asians (mostly from Chinese centres in this particular trial) with type 2 diabetes, thereby highlighting the heterogeneity of risk of diabetes complications (and costs) in different populations.
This study also provided important tools to facilitate estimation of healthcare expenditure associated with diabetes in different healthcare settings. At the time of the study, it was estimated that the average annual per capita health expenditure was approximately 216 international dollars in China, and 698 international dollars in Russia, but that the annual hospital costs for people with diabetes experiencing major macrovascular complications such as coronary or cerebrovascular events would be around four and ten times these average per capita expenditures. Perhaps not fully appreciated at the time was the significant burden associated with hospitalization with heart failure, which is a topic of much current interest in relation to recent advances in the treatment of type 2 diabetes.
Although the work was focused on evaluating the economic burden of diabetes in different parts of the world, this work can be considered as an important example of early attempts to deconstruct the heterogeneity of type 2 diabetes. As the diabetes epidemic continues unabated, the healthcare burden of diabetes complications has become a major concern globally.
2) Type 2 diabetes genetic loci informed by multi-trait associations point to disease mechanisms and subtypes: A soft clustering analysis
The second article, by Jose Florez and colleagues, utilized a state-of-the-art multi-omics approach to use available genetic and epigenomic data to probe the issue of heterogeneity of diabetes. The authors showed that identified genetic loci linked to diabetes can be segregated according to underlying biological mechanisms which can be used to classify individuals, to provide a way forward for individualized diagnosis, monitoring and treatment. The study highlighted the potential role of genetic variants related to the beta cell, pro-insulin, obesity, lipodystrophy and liver/lipid traits in accounting for different patient characteristics, as well as long-term diabetes outcomes.
What was particularly interesting is the soft-clustering approach adopted by the authors, which did not require genetic variants to fit into only one pathway, or for individuals to be classified to have diabetes due to only one specific pathophysiological defect, but instead, for individuals to be identified to have scores in each of the above-mentioned categories, and thereby accepting that individuals may have developed diabetes with different contribution from the different underlying pathophysiology. The use of such genetic risk scores may be useful in selecting the most appropriate therapies for individualized care in the future.
Over the last 15 years, the global burden of diabetes has more than doubled, from less than 200 million people affected back in the early 2000s to now more than 422 million people affected globally (with the majority in LMICs). These 2 articles represent important advances in our understanding of type 2 diabetes over the last decade. Whilst the ADVANCE study was a landmark study that generated much interest, the Clarke paper highlighted much of the burden of diabetes complications, and our lack of understanding regarding the heterogeneity in risk of diabetes complications. Together with the Action to Control Cardiovascular Risk in Diabetes (ACCORD) and Veterans Affairs Diabetes Trial (VADT) studies, these landmark studies, published between 2008-2010, have highlighted the potential dangers of hypoglycaemia, and heralded the debate and call for more individualized treatment in type 2 diabetes, and contributed to the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) to propose in their joint position statement on management of hyperglycaemia in type 2 diabetes in 2012 to move away from a one-size-fit-all approach to treatment, but instead adopt a treatment strategy that is more tailored to individual patient profile, disease duration, co-morbidities and expectations. This represented a major watershed moment in the evolution of diabetes research and care.
With recent advances in genomic medicine and the genetics of type 2 diabetes, some of which have been reported in PLOS Medicine, the era of precision medicine in diabetes is very much here to stay. We, as diabetes researchers and clinicians caring for people with diabetes, look forward to further advances in our understanding of how best to treat individuals with diabetes based on their underlying genetics, pathophysiology, and needs, and to improving outcomes for people with diabetes.
Congratulations again PLOS Medicine and we look forward to the next 15 years of exciting advances!
Ronald Ma is Professor and Head of Division of Endocrinology and Diabetes at the Department of Medicine and Therapeutics, The Chinese University of Hong Kong, and co-lead of the Chinese University of Hong Kong-Shanghai Jiao Tong University Joint Research Centre in Diabetes Genomics and Precision Medicine. He is a member of the Executive Board, Asian Association for the Study of Diabetes (AASD), and member of the editorial board of PLOS Medicine.
Acknowledgement: RCWM acknowledge support from the Hong Kong Research Grants Council Research Impact Fund (R4012-18).
Image Credit: stevepb, Pixabay (CC0)
See the original post here:
Charting the evolution of diabetes research and care | Speaking of Medicine - PLoS Blogs
- Gene therapy innovations: Sarepta and Codiak partner on exosomes - Pharmaceutical Technology - July 13th, 2020
- DNA research aims to take 'trial and error' out of depression medication treatment - ABC News - July 13th, 2020
- The Wilderness of Rare Genetic Diseases and the Parents Navigating It - The New York Times - July 13th, 2020
- Physicians, Patients Need to Know Limits of DNA Privacy Law - Medscape - July 13th, 2020
- African American, European Ancestry Men Benefit from Same Targeted Prostate Cancer Therapies - Clinical OMICs News - July 13th, 2020
- MyoKardia: The Precision Cardiac Medicine Company with Diversity and Inclusion at its Heart - BioSpace - July 13th, 2020
- Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Lumasiran - BioSpace - July 13th, 2020
- Largest-Ever Study of Prostate Cancer Genomics in Black Men IDs Potential Targets for Precision Therapies - UCSF News Services - July 13th, 2020
- Gene Editing Market Poised to Expand at a Robust Pace Over 2025 - 3rd Watch News - July 13th, 2020
- Uncovering the Unknowns to COVID-19 Testing | Center for Applied Genomics and Precision Medicine - Duke Today - July 13th, 2020
- Genetic Engineering Market Growing Rapidly with Significant CAGR, Leading Players, Innovative Trends and Expected Revenue by 2025 - Cole of Duty - July 13th, 2020
- NIH researchers reframe dog-to-human aging comparisons - National Institutes of Health - July 13th, 2020
- Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com - July 13th, 2020
- COVID-19: The lessons learned to date - Cosmos - July 13th, 2020
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of... - July 13th, 2020
- DNA Read, Write And Edit Market Sales Volume, Status, Growth, Opportunities and World the COVID-19 - 3rd Watch News - July 13th, 2020
- Jacobs School researchers collecting COVID-19 data - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter - July 13th, 2020
- Children's National Medical Center and AWS partner for genome project targeting COVID-19 - SiliconANGLE - July 6th, 2020
- Duke researchers help discover new strain of coronavirus that spreads faster because of gene mutation - WGHP FOX 8 Greensboro - July 6th, 2020
- Phenotype and Molecular Detection of Clarithromycin and Levofloxacin R | IDR - Dove Medical Press - July 6th, 2020
- EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer - Business Wire - July 6th, 2020
- Matteo Adinolfi obituary | From the Guardian - The Guardian - July 6th, 2020
- Inventiva announces the decision by the investigator to reduce the number of patients in the ongoing Phase II trial evaluating lanifibranor in type 2... - July 6th, 2020
- Bing and Ol' Medicine Hat - Todayville.com - July 6th, 2020
- Hansa Biopharma announces exclusive agreement with Sarepta Therapeutics to develop and promote imlifidase as pre-treatment ahead of gene therapy in se... - July 4th, 2020
- Movers & Shakers, July 3 | BioSpace - BioSpace - July 4th, 2020
- IHS Pets: Bringing Cell And Gene Therapy To Cats, Dogs & Horses - Anti Aging News - July 4th, 2020
- The Future of Medicine Is Bespoke - Fair Observer - July 4th, 2020
- Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer - GlobeNewswire - July 4th, 2020
- Massachusetts Eye and Ear Enters Licensing Agreement with Biogen to Develop Treatment for Inherited Retinal Disorder - Newswise - July 4th, 2020
- Eliminating the Long, Cumbersome and Costly Diagnosis of Genetic Diseases - HIT Consultant - July 4th, 2020
- Rare Disease Diagnostics Industry Anticipated to Reach $26.7 Billion by 2024 - Market Shares by Disease Class, Indication, Analysis Platform, Analysis... - July 4th, 2020
- 28 cool health things that started with a Canadian - Regina Leader-Post - July 4th, 2020
- Pools in the Mexican desert are a window into Earth's early life - Science Magazine - July 4th, 2020
- Personalized Cancer Drugs Market Expected to Witness a Sustainable Growth over 2025 - 3rd Watch News - July 4th, 2020
- Genetic Medicine will be the Solution to COVID-19, and Ligandal is Leading the way - PR Web - June 20th, 2020
- Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta's ImmTOR Immune Tolerance Platform in... - June 20th, 2020
- Researchers identify environmental components that affect gene expression in cardiovascular disease - The South End - June 20th, 2020
- FDA officials update on orphan drugs, gene therapies at DIA - Regulatory Focus - June 20th, 2020
- Cell and gene therapy-focused OpenCell Technologies hires MilliporeSigma executive Kevin Gutshall as new CEO - PRNewswire - June 20th, 2020
- Pfizer and Sangamo report positive data from hemophilia A therapy trial - Clinical Trials Arena - June 20th, 2020
- Regenerative Medicine Market to Record a Robust Growth Rate for the COVID-19 Period - Cole of Duty - June 20th, 2020
- UCLA receives nearly $14 million from NIH to investigate gene therapy to combat HIV - UCLA Newsroom - June 20th, 2020
- 15 Biotech Companies In Houston To Know - Built In - June 20th, 2020
- Ovid Therapeutics Receives FDA Rare Pediatric Disease Designation for OV101 for the Treatment of Angelman Syndrome - BioSpace - June 20th, 2020
- Global Precision Medicine Market Growth From 2019 to 2025- Market Report, Insights Analysis And Opportunities - Cole of Duty - June 20th, 2020
- Obesity in mice prevented by disabling gene - Medical News Today - May 24th, 2020
- COVID-19 study looks at genetics of healthy people who develop severe illness - Washington University School of Medicine in St. Louis - May 24th, 2020
- UBC scientist identifies a gene that controls thinness - UBC Faculty of Medicine - UBC Faculty of Medicine - May 24th, 2020
- IU team pursuing breathtaking advancements in regenerative medicine - The Republic - May 24th, 2020
- Complement genes add to sex-based vulnerability in lupus and schizophrenia - UAB News - May 24th, 2020
- COVID-19-Related Genes Have Higher Expression in Certain Patients With Asthma - Pulmonology Advisor - May 24th, 2020
- Precision Medicine Informs Cost-Effective Heart Disease Treatments - HealthITAnalytics.com - May 24th, 2020
- Here's Why Editas Could Beat Intellia to a CRISPR Therapy - Motley Fool - May 24th, 2020
- FDA Approves Genentech's Tecentriq as a First-Line Monotherapy for Certain People With Metastatic Non-Small Cell Lung Cancer - Business Wire - May 24th, 2020
- Doctors race to understand rare inflammatory condition associated with coronavirus in young people - Science Magazine - May 24th, 2020
- Retinoic acid synthesis by ALDH1A proteins is dispensable for meiosis initiation in the mouse fetal ovary - Science Advances - May 24th, 2020
- COVID-19 UPDATE: Precision Medicine Market 2020: Industry Analysis and Detailed Profiles of Top Industry Players are Neon Therapeutics, Moderna, Inc,... - May 24th, 2020
- A Coronavirus Vaccine Candidate In Six Days? This Company Is Fast-Tracking Vaccine Development With The First Fully Automated Gene Synthesis Platform... - May 24th, 2020
- IU team pursues breathtaking regenerative medicine advances - The Advocate - May 17th, 2020
- Precision medicine guides choice of better drug therapy in severe heart disease - Science Codex - May 17th, 2020
- Sarepta Therapeutics' (SRPT) "Buy" Rating Reiterated at Robert W. Baird - MarketBeat - May 17th, 2020
- Gene Editing Technologies in Diagnostic Platforms Market is expected to grow at a CAGR of 14.4% during the forecast period due to the rise in research... - May 17th, 2020
- Akouos to Present Data from Inner Ear Gene Therapy Platform at 23rd ASGCT Annual Meeting - Business Wire - May 14th, 2020
- Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases - GlobeNewswire - May 14th, 2020
- Gene therapy in mice builds muscle, reduces fat Washington University School of Medicine in St. Louis - Washington University School of Medicine in... - May 14th, 2020
- New Data for Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001 for Severe Hemoglobinopathies Accepted for Oral Presentation at the 25th European... - May 14th, 2020
- Gene therapy drug for infants priced at 170 million yen : The Asahi Shimbun - Asahi Shimbun - May 14th, 2020
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX001 for the... - May 14th, 2020
- Krystal Biotech Announces Positive Interim Results from Phase 1/2 Clinical Trial of KB105 in Patients with TGM1-related Autosomal Recessive Congenital... - May 14th, 2020
- bluebird bio to Present Data from Its Gene and Cell Therapy Programs During the Virtual Edition of the 25th European Hematology Association Annual... - May 14th, 2020
- Foundation Medicine and Collaborators to Share New Data During the ASCO20 Virtual Scientific Program Showcasing the Importance of Comprehensive... - May 14th, 2020
- Researchers: Disease affecting kids could be in the genes - Newsday - May 14th, 2020
- Tech optimization: Unlocking the promise of precision medicine - Healthcare IT News - May 14th, 2020
- FDA Approves RET Inhibitor Retevmo for Lung and Thyroid Cancer - Cancer Health Treatment News - May 14th, 2020
- The Cell Therapy Industry to 2028: Global Market & Technology Analysis, Company Profiles of 309 Players (170 Involved in Stem Cells) -... - May 14th, 2020
- INOVIO's INO-5401 in Combination with PD-1 Inhibitor Libtayo (cemiplimab) Demonstrates 85% of Newly Diagnosed Glioblastoma Patients Are Alive 12... - May 14th, 2020
- 21-Gene Recurrence Scores of 26 or Higher Can Help Determine If Chemotherapy Will Be Effective - MedicalResearch.com - May 14th, 2020
- Obesity prevented in mice treated with gene-disabling nanoparticles - Washington University School of Medicine in St. Louis - May 1st, 2020
- Optics makes amazing things possible in biological research and medicineand Optikos makes it happen - Mass Device - May 1st, 2020